Novel phosphoramidate derivatives of the anti-HIV nucleoside analogues AZT and d4T have been prepared by phosphorochloridate chemistry. These materials are designed to act as labile membrane-soluble prodrugs of the bio-active free nucleotides. All compounds were fully characterised by a range of methods and were subjected to evaluation in vitro of their anti-HIV efficacy. A notable feature of the current study was that any attempt to replace the amino acid moiety of the phosphoramidate with a simple amine lead to a marked, virtually total loss of activity. Such simple phenyl alkylamino phosphate derivatives of either d4T or AZT inhibit HIV replication at cytotoxic concentrations and have no detectable antiviral selectivity. This clearly highlights the Vital role played by the amino acid in the antiviral efficacy of the blocked phosphoramidates.
Introduction
In an attempt to improve on the therapeutic potential of current anti-HIV agents such as AZT 1 [1 in Fig. 1 ) reports have been produced on a variety of masked phosphate derivatives designed to act as membrane-soluble prodrugs of the bio-active phosphate forms (Freed et al., 1989; Farrow et el., 1990; McGuigan et al., 1990a,b,c; Henin et et., 1991; McGuigan et sl., 1991; McGuigan et et., 1992; Namane et el., 1992; Dessaux and Huynh-Dinh, 1993) . It was noted that diaryl phosphates derived from AZT are potent inhibitors of viral replication in vitro, in some cases being more potent than the parent nucleoside (McGuigan et et., 1994a) . However, detailed studies involving thymidine kinase-deficient cells indicate these compounds share a complete dependence on thymidine kinase-mediated phosphorylation for antiviral activity with the parent nucleoside. This strongly indicates that such compounds do not act as intracellular sources of the free nucleotides, as had been intended. These compounds appear, instead, to act as sources of the free nucleoside, presumably via nucleoside-phosphate cleavage rather than aryl-phosphate cleavage. However, observation of the retention of activity in cells lacking thymidine kinase for certain phosphoramidate derivatives of AZT (McGuigan et al., 1992) was taken as strong support for a mechanism of action independent of thymidine kinase. The simplest explanation of this is intracellular release of free nucleotides. Thus aryloxy phosphoramidates, such as compound 2 may represent true intracellular phosphate delivery forms (McGUigan et al., 1993a) . This technology has been recently applied to the promising nucleoside analogue d4T 3. Again, phosphoramldates appear to be effective prodrugs, with high potency and retention of activity in thymidine kinase-deficient cells (McGuigan et aI., 1993b; McGuigan et sl., 1996) . Moreover, when applied to nucleoside analogues which are poorly effective, or inactive, such as 2',3'-dideoxyuridine it has been noted that the phosphoramidates are effective inhibitors of viral replication (McGuigan et el., 1994b) . This process of activation of inactive nucleoside analogues has been termed 'kinase bypass' (McGuigan et al., 1990a; McGuigan et aI., 1994b) .
This phosphoramidate technology has also recently been applied to aza and deaza analogues of some purine nucleosides by other researchers (Franchetti et al., 1994) with notable success.
The exact mechanism by which aryloxy phosphoramidates exert their effect remains unclear, however. In this paper we report changes changes in the amino region of these compounds and demonstrates the vital importance of the amino acid moiety for antiviral activity.
Results
The synthetic strategy which has been used for the preparation of the aryloxy phosphoramidates closely follows what has been previously reported for earlier analogues (McGuigan et el., 1992; McGuigan et al., 1993a) . 
The synthetic route to novel nucleotide analogues; the structure of these and further nucleoside analogues.
This involves the initial preparation of the appropriate phosphorochloridate from phenyl phosphorodichloridate and an amine, followed by its reaction with the parent nucleoside analogue. However, whereas an amino acid ester hydrochloride has been used previously in the preparation of the phosphorochloridate, in this case an nalkylamine was used. By this method the phenyl alkylamino phosphorochloridates derived from n-propyl-, nbutyl-, n-pentyl-, n-hexyl-, n-octyl-, and n-dodecylamines were prepared. Unlike the phosphorochloridates derived from chiral amino acids, which generally displayed two closely spaced peaks in the P-31 NMR (McGuigan et el., 1993a) , these materials derived from simple amines displayed only one sharp singlet. However, the chemical shift was again ca. 12 ppm, which is entirely consistent with their structure (Mark et al., 1969) . Proton-and carbon-NMR data further confirmed the purity and structure of the phosphorochloridates. Thus, reaction of the phenyl butylamino compound with AZT in THF containing Nmethylimidazole gave 4a in moderate yield after purification by column chromatography. This was isolated as a mixture of diastereoisomers, as evidenced by the presence of two closely spaced signals in the P-31 NMR (op ca. 6ppm) -this arising from mixed stereochemistry at the phosphorus centre. The presence of these isomers was further confirmed in the H-1 NMR spectrum, where signals due to the base 5-methyl, and sugar H1' and H2' all showed extra multiplicities. Carbon-13 NMR data also confirmed the structure, purity, and isomeric nature of 4a. Full carbon-13 NMR data for this compound and each of the analogues described are given in Table 1 . Similarly prepared, in slightly higher yield, were the n-hexyl and ndodecyl analogues 4b-c. The d4T analogues 5a-f were then prepared by entirely analogous methods in yields of 72-88%. All spectroscopic data fully confirmed the structure and purity of these materials -each case again being isolated as an approximately 1:1 mixture of diastereoisomers about the phosphorus centre. All samples were pure by HPLC, and entirely free of any contaminating AZT or d4T; this is particularly important given the high activity of AZT in the biological assays used.
Discussion
The antiviral activities of compounds 1, 2, 3, 4a-c, 5a-f and the recently-prepared analogue 6 (McGuigan et al., 1996) were evaluated in two cell lines (human lymphocyte CEM/O and its thymidine kinase deficient CEMITK-counterpart) versus HIV-1 and HIV-2, with the resulting data shown in Table2. Thus, the previously reported amino acid-derived analogues 2 and 6 were again found to be very potent inhibitors of viral replication. In marked contrast to their parent nucleoside analogues they retained good activity in thymidine kinase-deficient cells. This is especially clear for the d4T analogue 6 where full activity is retained, indicating a complete independence of thymi- dine kinase-mediated activation in this case. However, it is a striking feature of the current data that all of the analogues derived from simple amines 4a-c and 5a-f are devoid of antiviral action at sub-cytotoxic concentrations.
To some extent the compounds appear to be more cytotoxic as the alkylamine chain length increases, but at no stage is there any indication of a significant selective antiviral effect. Thus, in conclusion we note the vital importance of the amino acid moiety for the antiviral efficacy of phenoxy phosphoramidates derived from either AZT or d4T. These data are complementary to recent observations (McGuigan et sl., 1993c) that the nature of the carboxyl ester terminus of certain phosphoramidates is important for antiviral activity. This would indicate the importance of the amino acid moiety per se, or at least the importance of a substituted amine. Whether the requirement is indeed for an amino acid, or whether other substituted amines are effective is the subject of current intensive study.
Materials and Experimental Procedures: Chemistry
All experiments involving water-sensitive compounds were conducted under scrupulously dry conditions. Triethylamine and dichloromethane were dried by heating under reflux over calcium hydride for several hours, followed by distillation. Oichloromethane was further dried over activated 4A molecular sieves. Tetrahydrofuran was dried by heating under reflux over sodium and benzophenone followed by distillation. Nmethylimidazole and simple alkylamines were purified by distillation where practical, otherwise by storage at elevated temperature in vacuo over P 20S ' Nucleosides were dried by the latter method. Proton, carbon and phosphorus Nuclear Magnetic Resonance CH, 13C, 31p nmr) spectra were recorded on a Bruker Avance OPX spectrometer (Bruker Spectrospin, SWitzerland-Germany) operating at 300MHz, 75.5MHz, and 121.5MHz respectively. All NMR spectra were recorded in COCI 3 at room temperature (20°C +1-3°C ). 1H and 13C chemical shifts are quoted in parts per million downfield from tetramethylsilane. J values refer to coupling constants and signal splitting patterns are described as singlet (s), broad singlet (bs), doublet (d), triplet (t), quartet (q), multiplet (m) or combinations thereof. 31p chemical shifts are quoted in parts per million relative to an external phosphoric acid standard. Many protonand carbon-NMR signals were split due to the presence of (phosphate) diastereoisomers in the samples. The mode of ionisation for mass spectroscopy unless stated was fast atom bombardment (FAB) with MNOBA as matrix. Chromatography refers to flash column chromatography and was carried out using Merck silica gel 60 (40-60Ilm) as stationary phase. Thin layer chromatography was performed using Alugram SIL G/UV 2 S 4 aluminium backed silica gel plates. HPLC was conducted on an ACS quaternary system, (ACS, Macclesfield, UK) using an 00S5 column and an eluant of water 1 acetonitrile, with 82% water 0-10 min, then a linear gradient to 20% water at 30 min, with a flow rate of 1 ml rnin" and detection by UV at 265nm.
General procedure for the preparation of Phenyl Nalkylamino phosphorochloridates A solution of triethylamine (2 mmol, 279 Ill) in dry dichloromethane (3 ml) was added dropwise, over one h, to a mixture of phenyl phosphorodichloridate (2 mmol, 422 mg) and the amine (2 mmol, 1 eq) in dry dichloromethane (10 ml) at -80°C . The reaction mixture was then stirred for 14-16 hours during which time the temperature rose to room temperature. The solvent was removed in vacuo and diethyl ether added to the residue (10 ml). Filtration of the precipitate and evaporation in vacuo afforded the tittle compound as a colourless oil which was used without further purification.
General procedure for the preparation of nucleotide derivatives (4a-c, Sa-f).
A solution (1 mmol mr') of freshly prepared phenyl N-alkyl phosphorochloridate (33.8 mmol, 2eq) in THF was added to a stirred solution of d4T (56 mg, 0.25 mmol) and N-methyl imidazole (80 Ill, 1 mmol, 4eq) in dry THF (1 ml). After 4 h, the solvent was removed under reduced pressure. The gum was dissolved in chloroform (10 ml), and washed with 1M HCI (8 ml), sodium bicarbonate (10 ml) and brine (15 ml). The organic phase was dried (MgS0 4), filtered and the solvent removed in vacuo. The residue was purified by column chromatography on silica with elution by chloroform-methanol (98:2) . Pooling and evaporation of the eluant gave the product as a white foam. AZT derivatives (4a-c) were similarly prepared.
3 
Yield=64%. 31p NMR 8 5.85,6.02; 1H NMR 0 0.90 (m, 3H, Me); 1.21, 1.35 (m, 2H, CH 2); 1.70, 1.73 (2s, 3H, 5-Me); 1. 2H, H2'); 2.91 (m, 2H, NCH 2); 2H, H4', NH); 4.26 (m, 3H, H5', H3'); 6.12, 6.18 (2 t, J=6.4 Hz, 1H, H1'); 6H, H6, Ph); 10.30 (s, 1H, NH) ; FAB MS m/e 479.1808(MW, C2oH28N606P requires 479.1808); HPLC retention time 27.0, 27.1 min (1:1) (see Materials and Experimental Procedures for conditions).
phosphate 4b
Yield =44%. 31p NMR 8 5. 74, 5.90 ; 1H NMR 8 0.85 (t, J = 7.5 Hz, 3H, Me); 1.25 (m, 6H, CH 2); 1.45 (m, 2H, CH 2); 1.83, 1.88 (2s, 3H, 5-Me); 2.07, 2.20 (2m, 1H, H2'); 2.35 (m, 1H, H2'); 2.90 (m, 2H, NCH 2); 3.72 (m, 1H, H4'); 4.05 (sb, 1H, NH); 4.30 (m, 3H, H5', H3'); 6.16, 6.20 (2t, J=6.4Hz , 1H, H1'); 7.12-7.38 (m, 6H, H6, Ph); 10.12 (s, 1H, NH); HPLC retention time 28.9, 29.2min (1:1).
3'-azido-3'-deoxy thymidine-5'-(phenyl Ndodecylamino)phosphate 4c
Yield =73%. 31p NMR 8 5.67, 5.83; 1H NMR 8 0.87 (t, J = 7.5 Hz, 3H, Me); 1.25, 1.43 (2m, 20H, CH 2); 1.87, 1.91 (2s, 3H, 5-Me); 2.09, 2.20 (2m, 1H, H2'); 2.35 (m, 1H, H2'); 2.94 (m, 2H, NCH 2); 4.03 (m, 1H, H4'); 4.33 (m, 3H, H5', H3'); 6.18, 6.24 (2 t, J=6.4Hz, 1H, H1'); 7.10-7.38 (m, 6H, H6, Ph); 9.87 (s, 1H, NH); FAB MS m/e 591.3058(MW, C28H44N606P requires 591.3060); HPLC retention time 38.5, 38.7 min (1:1). 2', phosphate Sa Yield = 83%. 31 P NMR 8 6.15, 6.81; 1H NMR 8 0.96 (t, J= 7.5 Hz, 3H, Me); 1.55 (m, 2H, CH 2); 1.90, 1.94 (2s, 3H, 5-Me); 2.96 (m, 2H, NCH 2); 3.41 (m, 1H, NH); 4.34 (m, 2H, H5'); 5.08 (m, 1H, H4'); 5.93 (m, 1H, H2'); 6.38 (m, 1H, H3'); 7.10 (m, 1H, H1'); 7.17-7.39 (m, 6H, H6, Ph); 9.61 (bs, 1H, NH); FAB MS m/e 444(MNa+, 32%), 422(M+, 24); HPLC retention time 29.9 min. 2', 
phosphate 5b
Yield =84%. 31p NMR 8 6.02, 6.69; 1H NMR 8 0.98 (t, J= 7.5 Hz, 3H, Me); 1.40 (m, 2H, CH 2); 1.56 (m, 2H, CH 2); 1.96, 2.00 (2s, 3H, 5-Me); 3.07 (m, 2H NCH 2); 3.22 (rn, 1H, NH); 4.44 (rn, 2H, H5'); 5.17 (m, 1H, H4'); 6.02 (m, 1H, H2'); 6.48 (m, 1H, H3'); 7.17 (m, 1H, H1'); 7.28-7.50 (rn, 6H, H6, Ph); 9.25 (bs, 1H, NH); FAB MS m/e 458(MNa+, 78%), 436(M+, 40); HPLC retention time 32.1 min.
Phosphoramidates of d4T and AZT 35
CEM cells mr' were infected with HIV-1 or HIV-2 at 100 CCID so (50% cell culture infective dose) perml of cell suspension. Then, 100111 of the infected cell suspension were transferred to microtitre plate wells and mixed with 100111 of the appropriate dilutions (111M -0.2 -0.04 -0.008 -0.0016 -0.0003IlM) of the test compounds. After 4 days giant cell formation was recorded microscopically in the HIV-infected cell cultures. The 50% effective concentration (EC so) and 50% cytotoxic concentration (CC so) were defined as the compound concentrations required to reduce by 50% the number of giant cells in the virus-infected cell cultures, and the number of viable cells (trypan blue exclusion method) in the mock-infected cell cultures respectively. The results quoted are the basis of 2 to 3 independent experiments carried out on separate occasions (data not shown).
